Patents by Inventor Zhengming Chen

Zhengming Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10638771
    Abstract: The present invention relates to a mutant strain of Lactococcus lactis and its application, and belongs to the field of food biotechnology. The mutant strain, Lactococcus lactis WH101, was screened for its better tolerance to harsh environmental factors, especially higher acid tolerance. The OD600 of Lactococcus lactis WH101 was increased by 5.5 times than that of the parent strain when cultured at pH 4.5. The survival rate of the mutant strain was 22.4 times higher than that of the parent strain after 3 hr treatment in pH 4.0 culture medium. The survival rate of the mutant strain was 5.2, 2.0 and 1.9 times over that of the parent strain treated with 15% ethanol for 4 hr, 15% NaCl for 6 hr and 1 mM H2O2 for 3 hr, respectively.
    Type: Grant
    Filed: July 3, 2017
    Date of Patent: May 5, 2020
    Assignee: Jiangnan University
    Inventors: Juan Zhang, Zhengming Zhu, Jian Chen, Guocheng Du, Peishan Yang
  • Patent number: 10596118
    Abstract: An ospemifene solid dispersion for enhancing solubility and bioavailability, and methods of preparation thereof are disclosed. The solid dispersion comprises an active pharmaceutical ingredient, such as ospemifene, and a hydfophilie carrier, such as copovidone, hypromellose acetate succinate, polyvinylpyrrolidine, a polyvinylpyrrolidine/vinyl acetate co-polymer, hydroxyl propyl methylcellulose, hypromellose acetate succinate, a Eudragit® compound, hydroxypropylcellulose, a polyvinyl caprolactam-polyvinyl acetate polyethylene glycol graft co-polymer, hydroxypropyl methylcellulose phthalate, and mixtures thereof, and optionally a surfactant The ospemifene solid, dispersions can be used in methods of treating a symptom related, to menopause, such as vaginal dryness or sexual dysfunction, or in methods of treating osteoporosis.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: March 24, 2020
    Assignee: Shionogi, Inc.
    Inventors: Zhengming Chen, Xiaoming Chen, Kevin Halloran
  • Publication number: 20190070148
    Abstract: The invention provides novel, multiply-substituted 1-aryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including depression and anxiety.
    Type: Application
    Filed: July 5, 2018
    Publication date: March 7, 2019
    Inventors: Phil SKOLNICK, Anthony BASILE, Zhengming CHEN, Joseph W. EPSTEIN
  • Patent number: 10039746
    Abstract: The invention provides novel, multiply-substituted 1-aryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including depression and anxiety.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: August 7, 2018
    Assignee: OTSUKA AMERICA PHARMACEUTICAL, INC.
    Inventors: Phil Skolnick, Anthony Basile, Zhengming Chen, Joseph W. Epstein
  • Publication number: 20180036245
    Abstract: An ospemifene solid dispersion for enhancing solubility and bioavailability, and methods of preparation thereof are disclosed. The solid dispersion comprises an active pharmaceutical ingredient, such as ospemifene, and a hydfophilie carrier, such as copovidone, hypromellose acetate succinate, polyvinylpyrrolidine, a polyvinylpyrrolidine/vinyl acetate co-polymer, hydroxyl propyl methylcellulose, hypromellose acetate succinate, a Eudragit® compound, hydroxypropylcellulose, a polyvinyl caprolactam-polyvinyl acetate polyethylene glycol graft co-polymer, hydroxypropyl methylcellulose phthalate, and mixtures thereof, and optionally a surfactant The ospemifene solid, dispersions can be used in methods of treating a symptom related, to menopause, such as vaginal dryness or sexual dysfunction, or in methods of treating osteoporosis.
    Type: Application
    Filed: March 10, 2016
    Publication date: February 8, 2018
    Inventors: Zhengming CHEN, Xiaoming CHEN, Kevin HALLORAN
  • Publication number: 20180000777
    Abstract: The invention provides novel, multiply-substituted 1-aryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including depression and anxiety.
    Type: Application
    Filed: July 12, 2017
    Publication date: January 4, 2018
    Inventors: Phil SKOLNICK, Anthony BASILE, Zhengming CHEN, Joseph W. EPSTEIN
  • Patent number: 9737506
    Abstract: The invention provides novel, multiply-substituted 1-aryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including depression and anxiety.
    Type: Grant
    Filed: November 1, 2015
    Date of Patent: August 22, 2017
    Assignee: NEUROVANCE, INC.
    Inventors: Phil Skolnick, Anthony Basile, Zhengming Chen, Joseph W. Epstein
  • Publication number: 20170204088
    Abstract: The invention provides novel 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including but not limited to depression and anxiety.
    Type: Application
    Filed: January 31, 2017
    Publication date: July 20, 2017
    Inventors: Phil Skolnick, Zhengming Chen
  • Patent number: 9597315
    Abstract: The invention provides novel 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including but not limited to depression and anxiety.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: March 21, 2017
    Assignee: EUTHYMICS BIOSCIENCE, INC.
    Inventors: Phil Skolnick, Zhengming Chen
  • Patent number: 9452974
    Abstract: Provided herein are compositions including diastereomers in substantially diastereomerically pure form and enantiomers in substantially enantiomerically pure form, and processes for preparing them and converting them to metyrosine.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: September 27, 2016
    Assignee: ATON PHARMA, INC.
    Inventors: Kevin John Halloran, Alex Comely, Zhengming Chen, Shyam Krishnan
  • Publication number: 20160158197
    Abstract: The invention provides novel, multiply-substituted 1-aryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including depression and anxiety.
    Type: Application
    Filed: November 1, 2015
    Publication date: June 9, 2016
    Inventors: Phil SKOLNICK, Anthony BASILE, Zhengming CHEN, Joseph W. EPSTEIN
  • Publication number: 20160022634
    Abstract: The invention provides novel 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including but not limited to depression and anxiety.
    Type: Application
    Filed: July 17, 2015
    Publication date: January 28, 2016
    Inventors: Phil Skolnick, Zhengming Chen
  • Patent number: 9205074
    Abstract: The invention provides novel, multiply-substituted 1-aryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including depression and anxiety.
    Type: Grant
    Filed: September 23, 2014
    Date of Patent: December 8, 2015
    Assignee: Neurovance, Inc.
    Inventors: Phil Skolnick, Anthony Basile, Zhengming Chen, Joseph W. Epstein
  • Patent number: 9133159
    Abstract: The invention provides novel 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including but not limited to depression and anxiety.
    Type: Grant
    Filed: April 3, 2013
    Date of Patent: September 15, 2015
    Assignee: NEUROVANCE, INC.
    Inventors: Phil Skolnick, Zhengming Chen
  • Publication number: 20150148399
    Abstract: The invention provides novel, multiply-substituted 1-aryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including depression and anxiety.
    Type: Application
    Filed: September 23, 2014
    Publication date: May 28, 2015
    Inventors: Phil SKOLNICK, Anthony BASILE, Zhengming CHEN, Joseph W. Epstein
  • Patent number: 9000174
    Abstract: The invention relates to piperidinyl compounds of Formula (I): or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein R1-R3 and Z are defined as set forth in the specification. The invention is also directed to an assay useful for identifying such compounds as N-type calcium channel modulators or blockers. The invention is also directed to the compounds of Formula (I) and compounds identified by the above assay, and the use of such compounds to treat, prevent or ameliorate a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.
    Type: Grant
    Filed: October 14, 2005
    Date of Patent: April 7, 2015
    Assignee: Purdue Pharma L.P.
    Inventors: Elfrida R. Benjamin, Zhengming Chen, Deyou Sha, Laykea Tafesse, Samuel F. Victory, John W. F. Whitehead
  • Publication number: 20140350284
    Abstract: Provided herein are compositions including diastereomers in substantially diastereomerically pure form and enantiomers in substantially enantiomerically pure form, and processes for preparing them and converting them to metyrosine.
    Type: Application
    Filed: August 8, 2014
    Publication date: November 27, 2014
    Inventors: Kevin John HALLORAN, Alex COMELY, Zhengming CHEN, Shyam KRISHNAN
  • Patent number: 8877798
    Abstract: The invention provides novel, multiply-substituted 1-aryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including depression and anxiety.
    Type: Grant
    Filed: May 5, 2013
    Date of Patent: November 4, 2014
    Assignee: Neurovance, Inc.
    Inventors: Phil Skolnick, Anthony Basile, Zhengming Chen, Joseph W. Epstein
  • Publication number: 20140303207
    Abstract: The invention provides novel 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including but not limited to depression and anxiety.
    Type: Application
    Filed: April 3, 2013
    Publication date: October 9, 2014
    Applicant: NEUROVANCE, Inc.
    Inventors: Phil SKOLNICK, Zhengming Chen
  • Patent number: 8841486
    Abstract: Provided herein are compositions including diastereomers in substantially diastereomerically pure form and enantiomers in substantially enantiomerically pure form, and processes for preparing them and converting them to metyrosine.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: September 23, 2014
    Assignee: Aton Pharma
    Inventors: Kevin John Halloran, Alex Comely, Zhengming Chen, Shyam Krishnan